Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12799MR)

This product GTTS-WQ12799MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12799MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14245MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ13730MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ8431MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ7675MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ9831MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ9379MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ5194MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ12896MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OPRX-106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW